| 中文名稱:EID3抗體 | 英文名稱:Rabbit Polyclonal EID3 Antibody |
| 品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
| 保存條件: Stored at -20°C for 2654 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
| 重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
| 種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
| 偶聯(lián)物: 無 | 靶點: EID3 |
| WB | 咨詢技術(shù) | Human,Mouse,Rat |
| IF | 咨詢技術(shù) | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
| FCM | 咨詢技術(shù) | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | NS4EB; NSE4B; NSMCE4B |
| WB Predicted band size | 38 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human EID3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse kidney tissue, Primary antibody: P04841(EID3 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute
The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P04841(EID3 Antibody) at dilution 1/15. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P04841(EID3 Antibody) at dilution 1/15. (Original magnification: ×200)
以下是關(guān)于EID3抗體的虛構(gòu)參考文獻示例(僅供格式參考,內(nèi)容非真實文獻):
1. **"EID3 regulates chromatin remodeling in breast cancer via histone acetylation"**
- **作者**: Feng Y, et al.
- **摘要**: 本研究利用EID3特異性抗體,通過ChIP-seq技術(shù)揭示EID3通過抑制組蛋白乙酰轉(zhuǎn)移酶EP300.調(diào)控乳腺癌細胞染色質(zhì)重塑,促進腫瘤轉(zhuǎn)移的分子機制。
2. **"Development and validation of a monoclonal antibody for EID3 in stem cell differentiation"**
- **作者**: Kim S, et al.
- **摘要**: 報道一種新型EID3單克隆抗體的開發(fā)與驗證,證明其在人胚胎干細胞分化模型中可特異性識別EID3蛋白,并揭示EID3通過Wnt信號通路抑制分化的功能。
3. **"EID3-antibody-based profiling identifies its role in neuronal development"**
- **作者**: Patel R, et al.
- **摘要**: 通過免疫組織化學(IHC)結(jié)合EID3抗體,發(fā)現(xiàn)EID3在小鼠大腦皮層神經(jīng)元發(fā)育中高表達,并參與調(diào)控神經(jīng)前體細胞的增殖與遷移。
4. **"EID3 interacts with p53: Insights from co-immunoprecipitation studies"**
- **作者**: Zhang L, et al.
- **摘要**: 使用EID3抗體進行免疫共沉淀實驗,證實EID3與腫瘤抑制因子p53直接結(jié)合,調(diào)控DNA損傷應(yīng)答,為癌癥治療提供潛在靶點。
注:以上文獻為模擬內(nèi)容,實際研究中建議通過PubMed、Web of Science等數(shù)據(jù)庫檢索真實文獻。
The EID3 (EP300 Interacting Inhibitor of Differentiation 3) antibody is a tool used to study the EID3 protein, a member of the EID family known for regulating transcription by interacting with EP300—a histone acetyltransferase (HAT) critical for chromatin remodeling and gene expression. EID3 functions as an inhibitor by binding to EP300. suppressing its HAT activity, and modulating downstream transcriptional programs. This interaction plays roles in cellular processes like differentiation, proliferation, and apoptosis, with implications in cancer, stem cell biology, and developmental disorders.
The EID3 antibody enables detection and analysis of EID3 protein expression, localization, and interactions in various experimental setups, including Western blotting, immunoprecipitation, and immunofluorescence. Researchers employ it to explore EID3's regulatory mechanisms in diseases, particularly cancers where EP300/EID3 dysregulation may drive tumor progression. Studies also investigate its role in epigenetic modifications and cellular reprogramming.
Developed for specificity and sensitivity, the antibody supports both basic research and translational studies aiming to dissect EID3's contribution to signaling pathways or evaluate its potential as a therapeutic target. Its utility spans molecular biology, oncology, and epigenetics, offering insights into how EID3-mediated transcriptional repression influences health and disease.
| 成立日期 | 2024-06-24 (3年) | 注冊資本 | 50萬(元) |
| 員工人數(shù) | 1-10人 | 年營業(yè)額 | ¥ 100萬以內(nèi) |
| 主營行業(yè) | 中間體,化學試劑 | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| ¥960.00 |
VIP11年
|
北京索萊寶科技有限公司
|
2026-07-23 | |
| ¥1800 |
VIP2年
|
費雪(杭州)醫(yī)學研究有限公司
|
2026-07-16 | |
| 詢價 |
VIP4年
|
維百奧(北京)生物科技有限公司
|
2026-05-28 | |
| ¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 |